登录注册

Tumor-infiltrating plasma cell targets as a source for immunotherapies

Cancer Cell (27 July 2026)

Tumor-infiltrating plasma cells are key responders to immunotherapy. In this issue of Cancer Cell, Meyerhoff et al. show that plasma cells from lung lesions of anti-PD-1-treated patients target citrullinated proteins. Engineering CAR T cells with these plasma cells scFv reveals anti-tumor specificity without adverse effects, identifying therapeutic opportunities.

Related products

Catalog No.	Product Name	Description	Target
HX959021	Recombinant Human CD269/TNFRSF17/BCMA Protein	Recombinant Human CD269/TNFRSF17/BCMA Protein, C-Fc (HX959021) expressed in Mammalian Cells, spanning Leu2-Ala54. Purity: >90% by SDS-PAGE. Highlights ●Fc Fusion — Enhanced stability with Protein A/G purification compatibility. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE.

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

鄂ICP备2023002448号-2

重组蛋白

抗体

试剂盒

实验相关试剂

Tumor-infiltrating plasma cell targets as a source for immunotherapies